Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a,bN0M0)

Cancer

Volumn 79, Issue 4, 1997, Pages 761-771

  Lee, Arthur K C ^a,b,e,f   Loda, Massimo ^b   Mackarem, Gasan ^a   Bosari, Silvano ^d   DeLellis, Ronald A ^c   Heatley, Gerald J ^a   Hughes, Kevin ^a  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e Hong Kong Baptist Hospital   (Hong Kong)

^f Lahey Hospital and Medical Center   (United States)

Author keywords

axillary lymph node negative; grade; prognostic parameters; small invasive breast carcinomas

Indexed keywords

KI 67 ANTIGEN; PROTEIN BCL 2;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-ABL; RECEPTORS, CELL SURFACE;

EID: 0031053407     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970215)79:4<761::AID-CNCR13>3.0.CO;2-Y     Document Type: Article

References (45)

1. Osteen RT, Cady B, Chmiel J, Clive R, Soggett RLS, Friedman M. 1991 National Survey of carcinoma of the breast by the commission on cancer. J Am Coll Surg 1994;178:213-9.
2. Jacobson JA, Danforth DN, Cowan KH, D'Angelo T, Steinberg SM, Pierce L, et al. Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med 1995;332:907-11.
3. DeVita VT Jr. Breast cancer therapy: exercising all our options [editorial]. N Engl J Med 1989;320:527-9.
4. NIH Consenusu Conference. Treatment of early-stage breast cancer. JAMA 1991;265:391-5.
5. Hillner BE, Smith TJ. Efficacy and cost effectiveness of adjuvant chemtherapy in women with node-negative breast cancer. N Engl J Med 1991;324:160-8.
6. McGuire WL, Clark GM. Current concepts: prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 1992;236:1756-61.
7. Rosner D, Lane WW. Predicting recurrence in axillary-node negative breast cancer patients. Breast Cancer Res Treat 1993;25:127-39.
8. American Joint Committee on Cancer. Manual for staging of cancer. Beahrs OH, Henson DE, Hutter RVP, Hennedy Bj editors. 1992;149-54.
9. Lee AKC, DeLellis RA, Silverman ML, Heatley GJ, Wolfe HJ. Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast. J Clin Oncol 1990;8:1457-65.
10. Bosari S, Lee AKC, DeLellis RA, Wiley BD, Heatley GJ, Silverman ML. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 1992;23:755-61.
11. Nasser IA, Lee AKC, Bosari S, Saganich R, Heatley GJ, Silverman ML. Occult axillary lymph node metastases in "node-negative" breast carcinoma. Hum Pathol 1993; 24:950-7.
12. Bosari S, Lee AKC, Tahan S, Figoni MAT, Wiley BD, Heatley GJ, et al. DNA flow cytometric analysis and prognosis of axillary lymph node-negative breast carcinoma. Cancer 1992;70:1943-50.
13. Bosari S, Lee AK, Viale G, Heatley GJ, Coggi G. Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long-term follow-up. Virch Arch A Pathol Anat Histopathol 1992;421:291-5.
14. Silverstein MJ, Gierson ED, Waisman JR, Colburn WJ, Bamagami P. Predicting axillary node positivity inpatients with invasive carcinoma of the breast by using a combination of T category and palpability. J Am Coll Surg 1995;180:700-4.
15. Fisher ER. Prognostic and therapeutic significance of pathological features of breast cancer. Natl Cancer Inst Monogr 1986;1:29-34.
16. Page DL. Prognosis and breast cancer. Recognition of lethal and favorable prognostic types. Am J Surg Pathol 1991; 15:334-49.
17. Berg JW, Hutter RVP. Breast cancer. Cancer 1995;75:257-69.
18. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer: a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957;11:359-77.
19. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
20. McDivitt RW, Boyce W, Gersell D. Tubular carcinoma of the breast. Clinical and pathological observations concerning 135 cases. Am J Surg Pathol 1982;6:401-11.
21. Leong AS-Y, Milios J. Comparison of antibodies to estrogen and progesterone receptors and the influence of microwave-antigen retrieval. Appl Immunohistochem 1994;1:282-8.
22. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, et al. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994;86:499-504.
23. Lee AK, Wiley BD, Loda M, Bosari S, Dugan JM, Hamilton W, et al. DNA ploidy, proliferation and n e u-oncogene over-expression in breast carcinoma. Mod Pathol 1992;5:61-7.
24. Keshgegian AA, Cnaan A. Proliferation markers in breast carcinoa. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am J Clin Pathol 1995;104:42-9.
25. Remmele W, Muhlfait V, Keul HG. Estimation of the proliferative activity of human breast cancer tissue by means of the Ki-67 and MIB-1 antibodies - comparative studies on frozen and paraffin sections. Virchow Arch A Pathol Anat Histopathol 1995;426:435-9.
26. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-87.
27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
28. Tarone R, Ware J. On distribution-free tests for equality of survival distributions. Biometrika 1977;64:156-60.
29. Rothman KJ, Boice JD Jr. Epidemiological analysis with a programmable calculator. New edition. Boston: Epidemiology Resources, Inc., 1982.
30. Cox DR. Regression models and life tables. J R Stat Soc 1972;34(Series B):187-220.
31. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63:181-7.
32. Fisher B, Slack NH, Bross IDJ. Cancer of the breast: size of neoplasm and prognosis. Cancer 1969;24:1071-80.
33. Huseby RA, Ownby HE, Frederick J, Brooks S, Russo J, Brennan MJ, et al. Node-negative breast cancer treated by modified radical mastectomy without adjuvant therapies: variables associated with disease recurrence and survivorship. J Clin Oncol 1988;6:83-8.
34. Koscielney S, Tubiana M, Le MG, Valleron AJ, Mouriess H, Contesso G, et al. Breast cancer: relationship between the size of the primary tumor and the probability of metastatic dissemination. Br J Cancer 1984;49:709-15.
35. Mansour EG, Ravdin PM, Dressier L. Prognostic factors in early breast carcinoma. Cancer 1994;74:381-400.
36. Rosen PP, Groshen S, Kinne DW, Norton L. Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 TlNoMo/T2NoMo patients with long-term follow-up. J Clin Oncol 1993;11:2090-100.
37. Frost AH, Terahata S, Yeh I-T, Siegel RS, Overmoyer B, Silverberg SG. An analysis of prognostic features in infiltrating lobular carcinoma of the breast. Mod Pathol 1995;18:830-6.
38. Seidman JD, Schnaper LA, Aisner SC. Relationship of the size of the invasive component of the primary breast carcinoma to axillary lymph node metastasis. Cancer 1995;75:65-71.
39. Rosner D, Lane WW, Penetrante R. Ductal carcinoma in situ with microinvasion. A curable entity using surger alone without need for adjuvant therapy. Cancer 1991;67:1498-503.
40. Leitner SP, Swern AS, Weinberger D, Duncan LJ, Hutter RVP. Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer (Tla.bNoMo). Cancer 1995;76:2266-74.
41. Clemente C, Boracchi P, Andreola S, Del Vecchio M, Veronesi P, Rilke FO. Peritumoral lymphatic invasion in patients with node-negative mammary duct carcinma. Cancer 1992; 69:1396-403.
42. Gasparini G, Weidner N, Bevilacqua P, Sergio M, Dalla Palma P, Caffo O, et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 1994;12:456-66.
43. Folkman J. Angiogenesis and breast cancer [editorial]. J Clin Oncol 1994;12:441-3.
44. Hayes DF. Angiogenesis and breast cancer [Review]. Hematol Oncol Clin North Am 1994;8:51-71.
45. Page DL. Angiogenesis in human breast carcinoma: what is the question? [editorial]. Hum Pathol 1995;26:1173-4.